Insulinoma future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 8: | Line 8: | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
The future therapies are being worked on [[Mammalian target of rapamycin|mTOR]] receptors. Drugs like Everolimus have been developed to prove their efficacy especially with those associated with [[MEN 1]] syndrome. | The future therapies are being worked on [[Mammalian target of rapamycin|mTOR]] receptors. Drugs like [[Everolimus]] have been developed to prove their efficacy especially with those associated with [[MEN 1]] syndrome. | ||
*It is thought that insulinoma is mediated by [[Mammalian target of rapamycin|mTOR]]/P70S6K [[signaling pathway]]. Thus, inhibitors of [[mTOR]] ([[rapamycin]]) or dual [[PI3K]]/[[Mammalian target of rapamycin|mTOR]] (NVP-BEZ2235) have become new drugs for treating insulinoma. | *It is thought that insulinoma is mediated by [[Mammalian target of rapamycin|mTOR]]/P70S6K [[signaling pathway]]. Thus, inhibitors of [[mTOR]] ([[rapamycin]]) or dual [[PI3K]]/[[Mammalian target of rapamycin|mTOR]] (NVP-BEZ2235) have become new drugs for treating insulinoma. | ||
*[[Everolimus]] (an oral [[Mammalian target of rapamycin|mTOR]] inhibitor) have better [[Glycemic control|glycemic control]] in people having an insulinoma.<ref name="pmid19129539">{{cite journal| author=Kulke MH, Bergsland EK, Yao JC| title=Glycemic control in patients with insulinoma treated with everolimus. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 2 | pages= 195-7 | pmid=19129539 | doi=10.1056/NEJMc0806740 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19129539 }} </ref><ref name="pmid22711648">{{cite journal| author=Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L et al.| title=Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. | journal=J Surg Oncol | year= 2012 | volume= 106 | issue= 8 | pages= 972-80 | pmid=22711648 | doi=10.1002/jso.23176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711648 }} </ref> | *[[Everolimus]] (an oral [[Mammalian target of rapamycin|mTOR]] inhibitor) have better [[Glycemic control|glycemic control]] in people having an insulinoma.<ref name="pmid19129539">{{cite journal| author=Kulke MH, Bergsland EK, Yao JC| title=Glycemic control in patients with insulinoma treated with everolimus. | journal=N Engl J Med | year= 2009 | volume= 360 | issue= 2 | pages= 195-7 | pmid=19129539 | doi=10.1056/NEJMc0806740 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=19129539 }} </ref><ref name="pmid22711648">{{cite journal| author=Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L et al.| title=Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis. | journal=J Surg Oncol | year= 2012 | volume= 106 | issue= 8 | pages= 972-80 | pmid=22711648 | doi=10.1002/jso.23176 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22711648 }} </ref> | ||
==References== | ==References== | ||
Revision as of 19:35, 17 October 2017
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Insulinoma future or investigational therapies |
|
Risk calculators and risk factors for Insulinoma future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
Overview
The future therapies are being worked on mTOR receptors. Drugs like Everolimus have been developed to prove their efficacy especially with those associated with MEN 1 syndrome and help maintain glycemic control in people having an insulinoma.
Future or Investigational Therapies
The future therapies are being worked on mTOR receptors. Drugs like Everolimus have been developed to prove their efficacy especially with those associated with MEN 1 syndrome.
- It is thought that insulinoma is mediated by mTOR/P70S6K signaling pathway. Thus, inhibitors of mTOR (rapamycin) or dual PI3K/mTOR (NVP-BEZ2235) have become new drugs for treating insulinoma.
- Everolimus (an oral mTOR inhibitor) have better glycemic control in people having an insulinoma.[1][2]
References
- ↑ Kulke MH, Bergsland EK, Yao JC (2009). "Glycemic control in patients with insulinoma treated with everolimus". N Engl J Med. 360 (2): 195–7. doi:10.1056/NEJMc0806740. PMID 19129539.
- ↑ Zhan HX, Cong L, Zhao YP, Zhang TP, Chen G, Zhou L; et al. (2012). "Activated mTOR/P70S6K signaling pathway is involved in insulinoma tumorigenesis". J Surg Oncol. 106 (8): 972–80. doi:10.1002/jso.23176. PMID 22711648.